Apatsara / Shutterstock.com
The Warner-Lambert v Actavis case concerning second medical use patents has resulted in a carefully considered judgment and there are some clear lessons to be learnt, says Arty Rajendra of Rouse Legal.
On September 10, 2015 Mr Justice Arnold gave his judgment in the Lyrica (pregabalin) case at the English High Court. UK legal commentators have described this dispute between Warner-Lambert (Pfizer) and Actavis and Mylan as ‘the case of the year’. The litigation has already spawned five previous judgments, mainly interim skirmishes between Warner-Lambert and Actavis, but also a related application against NHS England.
In his judgment disposing of the case at first instance, Arnold held that the relevant claims asserted against Actavis were invalid and that, in any event, Actavis was not infringing the patent. He also held that Warner-Lambert had made groundless threats of patent infringement proceedings against superintendent pharmacists, Murrays Pharmacy and clinical commissioning groups, among others. Warner-Lambert has a potential defence to this last finding but that will be heard separately.
The judgment is likely to be appealed so this is hardly the end of the story, but what lessons can be learned so far?
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Actavis, NHS, Arty Rajendra, pregabalin, Rouse, Warner-Lambert